RINVOQ® Approved for Kids 2+ with JIA and Psoriatic Arthritis
AbbVie announced that RINVOQ® (upadacitinib) is now approved in the U.S. for treating pediatric patients aged two years and older with active polyarticular juvenile idiopathic arthritis (pJIA) and psoriatic arthritis…
AbbVie Launches Phase 3 Trial for Multiple Myeloma Drug ABBV-383
Today, AbbVie announced the first patient has been treated with ABBV-383 in the CERVINO Phase 3 study. ABBV-383 is a bispecific antibody T-cell engager targeting BCMA and CD3, featuring high…
Incyte Completes Acquisition Of Escient Pharmaceuticals
Incyte has finalized its acquisition of Escient Pharmaceuticals, a company specializing in the development of small molecule therapeutics for immune and neuro-immune disorders. The acquisition enhances Incyte’s Inflammation and Autoimmunity…
WuXi Biologics Unveils 2023 ESG Report Showcasing Robust Sustainability Initiatives
WuXi Biologics, a prominent global Contract Research, Development, and Manufacturing Organization (CRDMO), has released its 2023 Environmental, Social, and Governance (ESG) Report, showcasing significant advancements in sustainable development. Aligned with…
BARDA Grants Qpex Biopharma, a Shionogi Group Entity, an Extra $10M to Boost Antibiotic Portfolio Combatting Drug-Resistant Infections
Shionogi & Co., Ltd. recently announced that its subsidiary, Qpex Biopharma, Inc., has exercised a $10 million option granted by the Biomedical Advanced Research and Development Authority (BARDA). This additional…
UCB’s BIMZELX[®]▼ (bimekizumab) 320 mg Device Earns Favorable CHMP Opinion
UCB, a leading global biopharmaceutical company, has announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has rendered a favorable opinion,…
Labcorp’s Assortment of Abstracts on Precision Oncology Featured at 2024 ASCO Annual Meeting
Labcorp, a renowned provider of cutting-edge laboratory services globally, is set to unveil multiple abstracts at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago from May…
FDA Recognizes Astellas’ Renewed Submission of Biologics License Application for Zolbetuximab and Establishes Revised Action Deadline
Today, Astellas announced that the U.S. Food and Drug Administration (FDA) has acknowledged the resubmission of the Biologics License Application (BLA) for zolbetuximab, a groundbreaking investigational monoclonal antibody targeting claudin…
Biogen’s QALSODY® (tofersen) Approved by European Commission for Rare Genetic ALS Treatment
The European Commission (EC) has granted marketing authorization, maintaining orphan designation, for QALSODY® (tofersen) to treat amyotrophic lateral sclerosis (ALS) in adults associated with a mutation in the superoxide dismutase…
Takeda Gets Favorable CHMP Opinion for rADAMTS13 in cTTP
Today, Takeda announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval, under exceptional circumstances, of recombinant ADAMTS13 (rADAMTS13) for treating…
Pfizer’s LORBRENA® CROWN Trial Reveals Prolonged Progression-Free Survival for Most ALK-Positive Advanced Lung Cancer Patients Over Five Years
Today, Pfizer released extended findings from the Phase 3 CROWN trial, examining the efficacy of LORBRENA® (lorlatinib), a third-generation ALK inhibitor, versus XALKORI® (crizotinib) in previously untreated patients with ALK-positive…
FDA Approves Bristol Myers Squibb’s Breyanzi for Relapsed/Refractory Mantle Cell Lymphoma CAR T Cell Therapy
The U.S. Food and Drug Administration (FDA) has approved Breyanzi® (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for adult patients with relapsed or refractory mantle…